Royalty Pharma (RPRX) to Release Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) is projected to post its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect Royalty Pharma to post earnings of $1.28 per share and revenue of $839.9730 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.

Royalty Pharma Stock Performance

Shares of RPRX opened at $44.65 on Monday. The firm has a fifty day moving average of $39.91 and a 200-day moving average of $38.02. The company has a market cap of $25.77 billion, a price-to-earnings ratio of 33.83, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma has a 1 year low of $29.66 and a 1 year high of $44.93.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio (DPR) is presently 71.21%.

Analyst Upgrades and Downgrades

Several brokerages have commented on RPRX. Citigroup raised their price target on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. UBS Group raised Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Friday, January 30th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday, January 22nd. Finally, TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.50.

Insiders Place Their Bets

In related news, EVP George W. Lloyd sold 132,426 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $38.34, for a total transaction of $5,077,212.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Terrance P. Coyne sold 114,954 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the completion of the sale, the chief financial officer owned 23,972 shares in the company, valued at approximately $1,026,960.48. This trade represents a 82.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,309,216 shares of company stock valued at $52,015,364. 18.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Royalty Pharma

Several hedge funds have recently made changes to their positions in the business. State Street Corp lifted its stake in Royalty Pharma by 0.8% during the third quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock valued at $362,423,000 after purchasing an additional 77,815 shares during the last quarter. Northern Trust Corp grew its position in Royalty Pharma by 1.3% in the third quarter. Northern Trust Corp now owns 4,075,239 shares of the biopharmaceutical company’s stock worth $143,774,000 after buying an additional 53,389 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Royalty Pharma by 10.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,282,174 shares of the biopharmaceutical company’s stock valued at $115,795,000 after buying an additional 305,694 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Royalty Pharma by 3.8% during the 3rd quarter. Legal & General Group Plc now owns 2,822,566 shares of the biopharmaceutical company’s stock valued at $99,580,000 after acquiring an additional 103,473 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Royalty Pharma by 29.7% during the 3rd quarter. Bank of America Corp DE now owns 2,646,772 shares of the biopharmaceutical company’s stock worth $93,378,000 after acquiring an additional 605,428 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.